Author + information
- Paul Chew, MD∗
- ↵∗Senior Vice President, Chief Medical Officer, Sanofi-Aventis Research and Development, Chilly-Mazarin, France
Sanofi currently holds marketing authorizations for hydroquinidine hydrochloride prolonged-release capsules in France since 1980 (Serecor 300 mg) and in Spain since 1973 (Lentoquine 250 mg).
In Israel, hydroquinidine is not registered but is supplied by Sanofi via a special institutional procedure authorizing the use of Serecor, upon request by Israeli medical institutions.
Hydroquinidine is an antiarrhythmic class IA medicine indicated for the prophylaxis and treatment of supraventricular arrhythmias or ventricular arrhythmias and the prevention of cardiac electric shock in some patients carrying implantable defibrillators. This product is particularly used for preventing life-threatening ventricular arrhythmias due to Brugada syndrome and idiopathic ventricular fibrillation.
Following the cessation of the activities of the third-party subcontractor responsible for manufacturing the hydroquinidine micro-granules used in Serecor prolonged release capsules, Sanofi has transferred the manufacturing process to 2 other third-party subcontractors.
Sanofi is continuously working in close cooperation with the French Health Authorities to comply with all regulatory requirements, to minimize the impact of these issues on supply to market and to maintain the availability of hydroquinidine.
- American College of Cardiology Foundation